Strides' board approves demerger of biotech business under Stelis Biopharma
The board will form a committee of directors to explore various options of value discovery including listing of the business on a standalone basis.04-02-2021
04-02-2021
Earnings Call for Q3FY21 of Strides Pharma Science
Conference Call with Strides Pharma Science Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.04-02-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached Press Release issued by the Company titled: 'Strides to Demerge and List its Biotech Business Under Stelis Biopharma'04-02-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Board of Directors of the Company in their meeting held today have allotted 10,400 equity shares of face value of Rs. 10/- each to the eligible employees who have exercised their stock options under Strides ESOP 2016 Plan. These shares shall rank in pari passu with the existing equity shares of the Company in all respects. Consequent to above, the paid-up share capital of the Company has increased from Rs. 89,63,54,140/- consisting of 8,96,35,414 equity shares of Rs. 10/- each to Rs. 89,64,58,140/- consisting of 8,96,45,814 equity share of Rs. 10/- each.04-02-2021
Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended December 31, 2020
We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and nine months ended December 31, 2020, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 11:15 hrs and concluded at 12:45 hrs. This is for your information and record.04-02-2021
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 03, 2021 for Pronomz Ventures LLP03-02-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for discussion of un-audited financial results for the quarter and nine months ended December 31, 2020.02-02-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
This has reference to our letter dated January 28, 2021 relating to intimation of Board Meeting scheduled to be held on Thursday, February 04, 2021, inter alia, to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2020. In compliance with Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, please find enclosed copies of newspaper advertisements published in Business Standard (English Edition) and Lokmat (Marathi Edition) on January 29, 2021. This is for your information and records.29-01-2021
Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2021 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, February 04, 2021, inter-alia, to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2020. Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed from Friday, January 1, 2021 to Saturday, February 6, 2021 (both days inclusive). This is for your kind information and record purposes.28-01-2021
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 27, 2021 for Pronomz Ventures LLP28-01-2021